Literature DB >> 31272578

Ulcerative Colitis.

Joseph D Feuerstein1, Alan C Moss2, Francis A Farraye3.   

Abstract

Ulcerative colitis (UC) is a chronic inflammatory bowel disease that can involve any aspect of the colon starting with mucosal inflammation in the rectum and extending proximally in a continuous fashion. Typical symptoms on presentation are bloody diarrhea, abdominal pain, fecal urgency, and tenesmus. In some patients, extraintestinal manifestations may predate the onset of gastrointestinal symptoms. A diagnosis of UC is made on the basis of presenting symptoms consistent with UC as well as endoscopic evidence showing continuous and diffuse colonic inflammation that starts in the rectum. Biopsies of the colon documenting chronic inflammation confirm the diagnosis of UC. Most cases are treated with pharmacological therapy to first induce remission and then to maintain a corticosteroid-free remission. There are multiple classes of drugs used to treat the disease. For mild to moderate UC, oral and rectal 5-aminosalycilates are typically used. In moderate to severe colitis, medication classes include thiopurines, biological agents targeting tumor necrosis factor and integrins, and the small-molecule Janus kinase inhibitors. However, in up to 15% of cases, patients in whom medical therapy fails or who have development of dysplasia secondary to their long-standing colitis will require surgical treatment. Finally, to minimize the complications of UC and adverse events from medications, a working collaboration between primary care physicians and gastroenterologists is necessary to make sure that vaccinations are optimized and that patients are screened for colon cancer, skin cancer, bone loss, depression, and other treatable and preventable complications.
Copyright © 2019 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 31272578     DOI: 10.1016/j.mayocp.2019.01.018

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  48 in total

1.  Identification of Differentially Expressed Genes and miRNAs for Ulcerative Colitis Using Bioinformatics Analysis.

Authors:  Weitao Hu; Taiyong Fang; Xiaoqing Chen
Journal:  Front Genet       Date:  2022-06-02       Impact factor: 4.772

2.  Inhibition of LncRNA-NEAT1 alleviates intestinal epithelial cells (IECs) dysfunction in ulcerative colitis by maintaining the homeostasis of the glucose metabolism through the miR-410-3p-LDHA axis.

Authors:  Siyi Ni; Yingchao Liu; Jihong Zhong; Yan Shen
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

3.  AGA Technical Review on the Role of Probiotics in the Management of Gastrointestinal Disorders.

Authors:  Geoffrey A Preidis; Adam V Weizman; Purna C Kashyap; Rebecca L Morgan
Journal:  Gastroenterology       Date:  2020-06-09       Impact factor: 22.682

4.  An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials.

Authors:  Christopher Ma; Rocio Sedano; Ahmed Almradi; Niels Vande Casteele; Claire E Parker; Leonardo Guizzetti; David F Schaeffer; Robert H Riddell; Reetesh K Pai; Robert Battat; Bruce E Sands; Christophe Rosty; Marla C Dubinsky; Florian Rieder; Noam Harpaz; Maria T Abreu; Robert V Bryant; Gregory Y Lauwers; Richard Kirsch; Mark A Valasek; Eileen Crowley; William J Sandborn; Brian G Feagan; Rish K Pai; Vipul Jairath
Journal:  Gastroenterology       Date:  2021-02-19       Impact factor: 22.682

5.  Combined effect of vitamin C and vitamin D3 on intestinal epithelial barrier by regulating Notch signaling pathway.

Authors:  Fubin Qiu; Zehui Zhang; Linxue Yang; Rui Li; Ying Ma
Journal:  Nutr Metab (Lond)       Date:  2021-05-08       Impact factor: 4.169

6.  Achieving Histologic Normalization in Ulcerative Colitis Is Associated With a Reduced Risk of Subsequent Dysplasia.

Authors:  Seth R Shaffer; Amarachi I Erondu; Cindy Traboulsi; Victoria Rai; Noa Krugliak Cleveland; Amanda Israel; Britt Christensen; David T Rubin
Journal:  Inflamm Bowel Dis       Date:  2022-03-30       Impact factor: 7.290

Review 7.  Therapeutic implications of inflammasome in inflammatory bowel disease.

Authors:  Vishal Khatri; Ramaswamy Kalyanasundaram
Journal:  FASEB J       Date:  2021-05       Impact factor: 5.834

Review 8.  Mucosal lesions of the upper gastrointestinal tract in patients with ulcerative colitis: A review.

Authors:  Yan Sun; Zhe Zhang; Chang-Qing Zheng; Li-Xuan Sang
Journal:  World J Gastroenterol       Date:  2021-06-14       Impact factor: 5.742

9.  Effects of Jian Pi Qing Chang Hua Shi decoction on mucosal injuries in a 2,4,6-trinitrobenzene sulphonic acid-induced inflammatory bowel disease rat model.

Authors:  Huicun Zhang; Na Ta; Hong Shen; Hongbing Wang
Journal:  Pharm Biol       Date:  2021-12       Impact factor: 3.503

10.  Exploring the Mechanism of Berberine Intervention in Ulcerative Colitis from the Perspective of Inflammation and Immunity Based on Systemic Pharmacology.

Authors:  Yan Jiang; Li Zhao; Qing Chen; Lihong Zhou
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-09       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.